170 related articles for article (PubMed ID: 25032186)
1. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation.
Lee JY; Kim YH; Yi NJ; Kim HS; Lee HS; Lee BK; Kim H; Choi YR; Hong G; Lee KW; Suh KS
Clin Mol Hepatol; 2014 Jun; 20(2):192-203. PubMed ID: 25032186
[TBL] [Abstract][Full Text] [Related]
2. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
[TBL] [Abstract][Full Text] [Related]
3. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
[TBL] [Abstract][Full Text] [Related]
4. Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma.
Kim JM; Hyuck C; Kwon D; Joh JW; Lee JH; Paik SW; Park CK
World J Surg; 2013 Jun; 37(6):1371-8. PubMed ID: 23443153
[TBL] [Abstract][Full Text] [Related]
5. Role of protein induced by vitamin-K absence-II in transplanted patients with HCC not producing alpha-fetoprotein.
Lai Q; Ito T; Iesari S; Ikegami T; Nicolini D; Larghi Laureiro Z; Rossi M; Vivarelli M; Yoshizumi T; Hatano E; Lerut J
Liver Transpl; 2024 May; 30(5):472-483. PubMed ID: 37729520
[TBL] [Abstract][Full Text] [Related]
6. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
[TBL] [Abstract][Full Text] [Related]
8. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma.
Xing T; Huang L; Yu Z; Zhong L; Wang S; Peng Z
PLoS One; 2013; 8(8):e71251. PubMed ID: 23940730
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
12. Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma.
Yang K; Lee TB; Choi BH; Park YM; Ryu JH; Joo DJ; Chu CW
Transplant Proc; 2016 Dec; 48(10):3317-3322. PubMed ID: 27931576
[TBL] [Abstract][Full Text] [Related]
13. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
[TBL] [Abstract][Full Text] [Related]
14. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation.
Lee KW; Suh SW; Choi Y; Jeong J; Yi NJ; Kim H; Yoon KC; Hong SK; Kim HS; Lee KB; Suh KS
Liver Transpl; 2017 Jan; 23(1):19-27. PubMed ID: 27540701
[TBL] [Abstract][Full Text] [Related]
15. Investigation of histological vascular invasion from preoperative evaluation in patients with hepatocellular carcinoma who underwent living donor liver transplantation.
Sakai K; Okajima H; Koshino K; Suzuki T; Nobori S; Matsuyama M; Ushigome H; Ochiai T; Yoshimura N
Transplant Proc; 2012 Mar; 44(2):409-11. PubMed ID: 22410029
[TBL] [Abstract][Full Text] [Related]
16. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
17. Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
Yoo T; Lee KW; Yi NJ; Choi YR; Kim H; Suh SW; Jeong JH; Lee JM; Suh KS
J Korean Med Sci; 2016 Jul; 31(7):1049-54. PubMed ID: 27366001
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection.
Yamanaka J; Yamanaka N; Nakasho K; Tanaka T; Ando T; Yasui C; Kuroda N; Takata M; Maeda S; Matsushita K; Uematsu K; Okamoto E
J Gastroenterol Hepatol; 2000 Oct; 15(10):1192-8. PubMed ID: 11106101
[TBL] [Abstract][Full Text] [Related]
20. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
